NEW YORK (TheStreet) -- Omeros (OMER) - Get Report shares are down 0.54% to $24 in after-hours trading on Monday following the release of the pharmaceutical company's fourth quarter financial results after the closing bell today.

Omeros reported a fourth quarter net loss of $20.7 million, or a 49 cent per share loss when adjusted for non-recurring losses on revenue of $180,000 during the period. Analysts on average were expecting the company to report a net loss of 60 cents per share on revenue of $151,700.

The stock is down despite beating analysts expectations as the 49 cents per share it lost this quarter is nearly 10 times the 5 cents per share the company reported losing during the same period last year.

TheStreet Ratings team rates OMEROS CORP as a Sell with a ratings score of D+. TheStreet Ratings Team has this to say about their recommendation:

"We rate OMEROS CORP (OMER) a SELL. This is driven by multiple weaknesses, which we believe should have a greater impact than any strengths, and could make it more difficult for investors to achieve positive results compared to most of the stocks we cover. The company's weaknesses can be seen in multiple areas, such as its weak operating cash flow, deteriorating net income and feeble growth in its earnings per share."

Highlights from the analysis by TheStreet Ratings Team goes as follows:

• You can view the full analysis from the report here: OMER Ratings Report

OMER

data by

YCharts